alobresib

N/A

Report date: 2022/07/19 20:00:45
NME

Base Information

Drug Namealobresib
Drug Alias NameGS-5829
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBromodomain and extra terminal domain protein inhibitors
TargetsBromodomain and extra terminal domain protein
Therapy Area/IndicationsSolid tumoursProstatic Neoplasms, Castration-ResistantBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGilead Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGilead Sciences Inc
Active IndicationsN/A
Inactive IndicationsSolid tumoursProstatic Neoplasms, Castration-ResistantBreast Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A